: Dose response curve for halofuginone and N-Boc-halofuginone in the [
3 H]-L-proline aminoacylation incorporation assay (10 nM PfProRS enzyme, 100 nM [
3 H]-L-proline, 100 M ATP and 400 g/ml yeast tRNA was incubated for 2 h at 25 C; Z' = .67). Lines are fit to a Hill Slope = 1 and IC50 for Halfuginone is calculated to be 0.011 µM and N-Boc-Halofuginone is >3 µM. Error bars indicate the standard deviation of triplicate samples for each experimental condition. 
Compound Name Canonical SMILES TCMDC-124506
Cn1nc(c(c2ccc(F)cc2)c1NC(=O)Nc3ccc(F)cc3)C(F)(F)F glyburide COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3 telmisartan CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C ( Table S2 : Percentage inhibition of ProRS enzyme (Pf = Plasmodium, Hs = human) activity by ATP-depletion assay. Full inhibition (100) was equivalent to controls of no enzyme or no substrate and no inhibition (0) was equivalent to all reagents with 2% DMSO (no compound). Percentage inhibition values are the average of measurements in triplicate. The simplified molecular-input line-entry system (SMILES) formula for each compound is indicated in the lower portion of the table. ] i ); the fluorescence ratios corresponding to 130 mM Na + and 0 mM Na + are shown. TCMDC-124506 and KAE609, but not DMSO, gave rise to an increase in [Na + ] i . B. The effects of various compounds on pH i in isolated 3D7 trophozoites. DMSO (0.1% v/v; solvent control) did not increase pH i , and on addition of the Vtype H + pump inhibitor concanamycin A (100 nM; red arrow) the pH i decreased to below the pH of the extracellular solution. TCMDC-124506 (tested at 5 M) and KAE609 (50 nM) caused an increase in pH i and a reduction in the extent of the concanamycin A-induced acidification. In A and B, the traces shown are from a single experiment, and are representative of those obtained in two similar experiments. 
A. IC50 of TCMDC-124506 as a function of proline B. Linear relationship with upward trend indicates competitive behavior of proline with TCMDC-124506
[TCMDC], M The experiments were run as described for the ATP consumption assay in the Materials and Methods except that the proline or the ATP was varied and the IC50 for TCMDC-124506 was determined for each condition.
[124506] M 
Supplemental Experimental Procedures Biology Methodology
Plasmodium falciparum screening Assays against P. falciparum were conducted as previously described (Trager and Jensen 1976; Bennett et al., 2004; Snyder et al., 2007) . Cultures of the widely-used malaria reference strain of chloroquine-sensitive Plasmodium falciparum strain 3D7 were maintained in a 5% suspension of human red blood cells (obtained from East of Scotland Blood Transfusion Service, Ninewells Hospital, Dundee) cultured in RPMI 1640 medium (pH 7.3) supplemented with 0.5% Albumax II (Gibco Life Technologies, San Diego, CA), 12 mM sodium bicarbonate, 0.2 mM hypoxanthine and 20 mg/L gentamicin at 37°C, in a humidified atmosphere of 1% O 2 , 3% CO 2 with a balance of nitrogen. Growth inhibition was quantified using a fluorescence assay utilising the binding of SYBR green to double stranded DNA, which emits a fluorescent signal at 528 nm after excitation at 485nm (Plouffe et al., 2008) . Mefloquine (potency range 30-60 nM) was used as a drug control to monitor the quality of the assay (Z' = 0.6 to 0.8, Signal to background >3, where Z' is a measure of the discrimination between the positive and negative controls on a screen plate). Compound bioactivity was expressed as EC 50 , the effective concentration of compound causing 50% inhibition of parasite growth.
Thermal Melt Analysis
Color fluorimetry experiments to measure changes in protein thermal stability were conducted as previously described (Vedadi et al., 2006) . Serial dilutions of the purified recombinant protein samples were prepared in 96 well PCR plates (Bio-Rad HSP9655) in a buffer containing 100mM HEPES, 150mM NaCl, pH 7.5 and SYPRO Orange Dye (Life Technologies S-6650). Protein stability for protein samples containing the substrates ATP and L-Proline were compared with apo protein samples by measuring an increase in fluorescence as detected on an MJ Research DNA Engine Opticon 2 qPCR thermocycler from 20C to 99C at half degree increments.
In vitro Cell Assay Data Analysis
All data was processed using IDBS ActivityBase ® raw data was converted into per cent inhibition through linear regression by setting the high inhibition control as 100% and the no inhibition control as 0%. Quality control criteria for passing plates were as follows: Z'> 0.5, S:B> 3, %CV (no inhibition control) < 15. The formula used to calculate Z' is .
All EC 50 Curve fitting was undertaken using XLFit version 4.2 using Model 205 with the following 4 parametric
,where A=% inhibition at bottom, B=% inhibition at top, C= EC 50 , D= slope, x= inhibitor concentration and y= % inhibition. If curve did not reach 100% of inhibition, B was fixed to 100 only when at least 50% of inhibition was reached.
Aqueous solubility
The aqueous solubility of the test compounds was measured using laser nephelometry, as described previously (Patterson et al., 2013) . Compounds were subject to serial dilution from 10 mg/mL to 0.5 mg/mL in DMSO. An aliquot was then mixed with MilliQ water to obtain an aqueous dilution plate with a final concentration range of 100 -5 μg/mL, with a final DMSO concentration of 1.0%. Triplicate aliquots were transferred to a flat bottomed polystyrene plate which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against compound concentration using a segmental regression fit, with the point of inflection being quoted as the compounds aqueous solubility (μg/mL). Assays were run in triplicate.
Intrinsic Clearance (CLi) experiments
The procedure was carried out as reported previously (Patterson et al., 2013) . Test compound (0.5 µM) was incubated with female CD1 mouse liver microsomes (Xenotech LLC TM ; 0.5 mg/mL 50 mM potassium phosphate buffer, pH 7.4) and the reaction started with addition of excess NADPH (8 mg/mL 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, then at 3, 6, 9, 15 and 30 min an aliquot (50 µL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to stop the reaction. Internal standard was added to all samples, the samples were centrifuged to sediment precipitated protein and the plates then sealed prior to UPLCMSMS analysis using a Quattro Premier XE (Waters Corporation, USA).
XLfit (IDBS, UK) was used to calculate the exponential decay and consequently the rate constant (k) from the ratio of peak area of test compound to internal standard at each timepoint. The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following calculation: CLi (mL/min/g liver) = k x V x Microsomal protein yield Where V (mL/mg protein) is the incubation volume/mg protein added and microsomal protein yield is taken as 52.5mg protein per g liver. Verapamil (0.5 µM) was used as a positive control to confirm acceptable assay performance. Experiments were performed using a single time-course experiment.
Ion homeostasis in the malaria parasite
To measure ion concentrations inside the parasite, P. falciparum trophozoites (3D7 strain) were isolated from their host erythrocytes by brief exposure to saponin (0.05% w/v final concentration), then loaded with either the Na (Spillman et al., 2013a) or the pHsensitive dye BCECF (for measurements of intracellular pH (pH i )) (Saliba and Kirk, 1999) . Fluorescence measurements and calibrations were performed at 37°C in the same manner described previously (Spillman et , 2013a; Lehane et al., 2014) . To test TCMDC-124506, 1 L of a DMSO stock of the compound was added to 1 mL of isolated parasites suspended in a saline solution (125 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 20 mM glucose, 25 mM HEPES; pH 7.10) at a density of ~ 3 × 10 7 parasites mL -1 to give the desired final concentration.
TCMDC-124506 gave rise to the ionic "signature" of PfATP4 inhibition that has been described previously for spiroindolones (Spillman et al., 2013a; Spillman et al., 2013b) and other chemically diverse compounds (Lehane et al., 2014) : it caused (i) an increase in the Na + concentration inside the parasite ( Figure S3A ), (ii) a cytosolic alkalinisation ( Figure S3B ), and (iii) a reduction in the extent of acidification seen following inhibition of the parasite's V-type H + pump with concanamycin A ( Figure S3B ).
Chemistry Experimental Section
Chemistry. General. Solvents and reagents were purchased from commercial suppliers and used without further purification. Dry solvents were purchased in sure sealed bottles stored over molecular sieves. H NMR spectra were recorded on a Bruker Avance DPX 500 spectrometer ( 1 H at 500.1 MHz), or a Bruker Avance DPX 400 ( 1 H at 400 MHz). Chemical shifts (δ) are expressed in ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broadened (br), or a combination thereof. Coupling constants (J) are quoted to the nearest 0.1 Hz. Low resolution electrospray (ES) mass spectra were recorded on a Bruker Daltonics MicroTof mass spectrometer, run in positive mode. LC-MS analysis, HRMS analysis and chromatographic separation were conducted with a Brucker Daltonics MicrOTOf mass spectrometer or an Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 quadrupole LC/MS, where both instruments were connected to an Agilent diode array detector. The column used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle size,) and the compounds were eluted with a gradient of 5 to 95% acetonitrile/water +0.1% Ammonia. All final compounds showed chemical purity ≥ 95% as determined by the UV chromatogram (190-450nm) obtained by LC-MS analysis and NMR. Unless otherwise stated herein reactions have not been optimized. Compounds 3 and 17 were purchased from Maybridge and tested without further purification after purity was determined to be ≥ 95% by the UV chromatogram (190-450nm) obtained by LC-MS analysis.
General procedure A. A mixture of ethyl 2,2,2-trifluoroacetate (1 g, 7.0 mmol) and the corresponding acetonitrile (1 eq) in dry THF (5 mL) was added to a stirred suspension of NaH (1.5 eq) in dry THF (5 mL) under nitrogen at 40 o C over the course of 30 min. After stirring at 40 o C for 2 hours, the reaction mixture was poured into water and acidified with HCl 3N and extracted with diethyl ether. The combined organic layers were dried over MgSO 4 and concentrated to give a crude material that was triturated using a mixture of CH 2 Cl 2 /petroleum ether and the solid was filtrated to obtain a first fraction of the desired compound. The CH 2 Cl 2 / petroleum ethers filtrate was concentrated under reduced pressure to obtain a mixture of product and starting materials. This mixture was triturated again with CH 2 Cl 2 / petroleum ethers to yield a second fraction of the desired product.
General Procedure B.
A solution of methylhydrazine (23 mg, 0.5 mmol) and the corresponding 3-oxobutanenitrile (1 eq) in methanol (1 mL) was heated at 100 o C for 1h under microwave irradiation. The solution was evaporated under reduced pressure and the resulting crude material purified by flash column chromatography using a silica cartridge eluting with 40% of ethyl acetate in heptane. The desired fractions were concentrated under reduced pressured to give the desired pyrazole as a solid.
General Procedure C. To a stirred solution of the desired pyrazol-5-amine (0.71 mmol) in THF (1 mL) the corresponding isocyanate (1.1 eq) was added and the reaction mixture was stirred at room temperature overnight. The reaction was concentrate to dryness and the crude material was purified by flash column chromatography using a silica cartridge eluting with 10% of ethyl acetate in heptane to give the desired pyrazol-5-yl-urea.
TCMC-125506 (1)
. Prepared according to general procedure A followed by general procedures B and C (85 mg, 83%). ¹H NMR (400 MHz, DMSO-d6)  7. 6H), 7.10 (dd, J=8.9, 8.9 Hz, 2H) 
1-(4-fluorophenyl)-3-(4-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea (7).
A solution of hydrazine hydrate (61 mg, 1.2 mmol, 1.4 eq) and 4,4,4-trifluoro-2-(4-fluorophenyl)-3-oxo-butanenitrile [7] (200 mg, 0.9 mmol) in acetic acid (1 mL) was stirred at room temperature overnight. The reaction mixture was then concentrated under reduced pressure and the residue partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (3x). The organic layers were combined and dried over MgSO 4 and concentrated under vacuum to give 4-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-amine (196 mg,0.9 mmol). 4-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-amine was then reacted with 1-fluoro-4-isocyanatobenzene following general procedure C to obtain 7 in 58% yield. ¹H NMR (500 MHz, DMSO-d6)  10.30 (s, 1H), 7. 71 -7.68 (m, 2H), 7.37 (dd, J=5.6, 8.5 Hz, 2H), 7.32 -7.21 (m, 4H), 6.64 (s, 2H).
1-(4-fluorophenyl)-3-(4-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea (8).
To a mixture of 4,4,4-trifluoro-2-(4-fluorophenyl)-3-oxo-butanenitrile (36 mg, 0.16 mmol) in acetic acid (0.5 mL), 2-hydrazinoethanol (12 mg,0.16 mmol) was added and the reaction stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the crude taken onto next step which was performed following general procedure C to obtain 8 (7 mg, 9%). ¹H NMR (400 MHz, DMSO-d6)  7.31 -7.22 (m, 6H), 7.14 -7.12 (m, 
2-(4-(4-fluorophenyl)-5-(3-(4-fluorophenyl)ureido)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetamide (9).
A mixture of 4,4,4-trifluoro-2-(4-fluorophenyl)-3-oxo-butanenitrile (140 mg,0.6 mmol) and ethyl 2-hydrazinoacetate hydrochloride (94 mg,0.6 mmol) in methanol (2 mL) was heated at 100 o C for 1h under microwave irradiation. The solvent was evaporated and the crude was taken up in ethyl acetate and washed with a saturated aqueous solution of NaHCO 3 . The organic layer was dried over MgSO 4 and solvents were evaporated under reduced pressure to obtain ethyl 2-[5-amino-4-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]acetate (131 mg, 65.291% yield). Without further purification, ethyl 2-[5-amino-4-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]acetate was then reacted with 1-fluoro-4-isocyanatobenzene following general procedure C to obtain ethyl 2-[4-(4-fluorophenyl)-5-[(4-fluorophenyl)carbamoylamino]-3-(trifluoromethyl)pyrazol-1-yl]acetate (99% yield) which was suspended in ammonium hydroxide solution (4 mL) and stirred at room temperature for 5h. The reaction was concentrated to dryness to obtain 9 (30 mg, 
1-(4-fluorophenyl)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea (10).
To a stirred solution of commercially available 2-methyl-5-(trifluoromethyl)pyrazol-3-amine (150 mg, 0.9 mmol) in THF (1.5 mL), 1-fluoro-4-isocyanato-benzene (125 mg, 0.9 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction was concentrate to dryness and the crude material was purified by trituration with petroleum ether to obtain 10 as a white solid (213 mg, 73% yield). ¹H NMR (500 MHz, DMSOd6)  9.05 (s, 1H), 8.89 (s, 1H), 7.48 (dd, J=4.9, 9.0 Hz, 2H), 7.14 (dd, J=8.9, 8.9 Hz, 2H), 6.60 (s, To a solution of 10 (1.2 g, 3.9 mmol) in acetonitrile (5 mL), NBS (0.77 g, 4.4 mmol) was added at room temperature. The reaction was stirred at room temperature for 1h. Solvent was evaporated under reduced pressure, the residue was taken up in DCM (10 mL) and washed with water (5 mL). Solvents were removed and product was purified by column chromatography using a 24 g silica cartridge using heptane (A) and ethyl acetate (B) as eluents and the following gradient: 1 min hold 100%A, 15 min ramp to 50% B, 1 min hold 50%B. Fractions containing product were pooled together and solvents were removed under reduced pressure to obtain 11 as a white solid (730 mg, 47 %). ¹H NMR (500 MHz, DMSO-d6)  9. 4-bromo-2-methyl-5-(trifluoromethyl)pyrazol-3-amine. To a solution of commercially available 2-methyl-5-(trifluoromethyl)pyrazol-3-amine (1.6 g, 10 mmol) in acetonitrile (5 mL) in an ice bath, NBS (1.7 g, 10 mmol) was added. The reaction mixture was stirred for 30 min in an ice bath. Solvents were evaporated under reduced pressure, the resulting residue was taken up in DCM (100 mL) and washed with water (20 mL). The organic phase was separated and dried over MgSO 4 . Solvents were removed under reduced pressure. The desired product was purified by column chromatography using a silica cartridge (24 g) and heptane (A) and ethyl acetate (B) as eluents and the following gradient: 1 min hold 100%A, 18 min ramp to 30% B, 1 min hold 30 %B. Fractions containing product were pooled together and solvents were removed under reduced pressure to obtain the title compound as a light pink solid (1.8 g, 73% yield). ¹H NMR (400 MHz, CDCl 3 )  3.77 (s, 3H). General Procedure E. To a solution of 4-bromo-2-methyl-5-(trifluoromethyl)pyrazol-3-amine (1 eq), palladium acetate (0.05 eq), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (X-Phos) (0.1 eq), and the corresponding boronic acid (1.5 eq) in toluene (3 mL) was added potassium phosphate (1.5 eq) in water (1 mL). The reaction was sealed and the mixture was stirred at 95 o C overnight. Reaction crude was filtered through Celite (5g cartridge) and Celite washed with DCM (10 mL). Reaction was partitioned between DCM (10 mL) and brine (5 mL). The organic layer was dried over MgSO 4 , solvents were evaporated under reduced pressure. The product was purified by column chromatography using silica cartridge (12 g) and heptane (A) and ethyl acetate (B) as eluents. 3,4-difluorophenyl)-1-methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)-3-(4-fluorophenyl)urea (12) To a solution of the (4-(3,4-difluorophenyl)-2-methyl-5-(trifluoromethyl)pyrazol-3-amine (140 mg, 0.4 mmol) in THF (10mL) at room temperature, 1-fluoro-4-isocyanato-benzene (183 mg, 1.3 mmol) was added and the reaction was stirred for two days at room temperature. The reaction mixture was concentrated to dryness under reduced pressure and the product was purified by preparative HPLC. Fractions containing product were pooled together and solvent was removed to obtain 12 as a white solid (55 mg, 28% yield). ¹H NMR (500 MHz, MeOD) 7.37 -7.23 (m, 4H), 7.17 -7.14 (m, 1H), 7.04 -7.00 (m, 2H), 3.86 (s, 3H 
LC-MS (ESI)

1-(4-(
1-(4-fluorophenyl)-3-(4-(2-(hydroxymethyl)phenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea (13)
To a stirred solution of [2-[5-amino-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]phenyl]methanol (138 mg, 0.51 mmol) in THF (10 mL) in an ice bath, 1-fluoro-4-isocyanato-benzene (70 mg, 0.51 mmol) was added and the reaction mixture was allowed to reach room temperature and stirred overnight. LCMS showed only unreacted starting material after stirring overnight. A further equivalent of 1-fluoro-4-isocyanatobenzene was added and the reaction stirred was stirred overnight at room temperature. The reaction was concentrate to dryness under reduced pressure and the crude material was purified by preparative HPLC. Fractions containing product were pooled together and solvent was removed to obtain 13 as a white solid (20 mg, 9% yield 
1-(4-fluorophenyl)-3-[4-[2-(2-hydroxyethyl)phenyl]-2-methyl-5-(trifluoromethyl)pyrazol-3-yl]urea (14) To a solution of 1-[4-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenyl]-2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-3-
(4-fluorophenyl)urea (20 mg, 0.04 mmol) in anhydrous methanol (3 mL) in a bath ice, acetyl chloride (0.5 L) was added. The reaction was allowed to reach room temperature and stirred for 3 hours. Solvents were removed and product was purified by preparative HPLC. Solvents were removed to obtain 14 as a white solid (10 mg, 63% 
2-[3-[5-amino-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]phenyl]ethanol. Prepared according to general
procedure E starting from 4-bromo-2-methyl-5-(trifluoromethyl)pyrazol-3-amine (190 mg, 0.78 mmol) to obtain the desired product (86 mg, 36% yield). ¹H NMR (500 MHz, MeOD) 7.31 -7.27 (m, 1H), 7.17 -7.10 (m, 3H), 3.75 (t, J=6.9 Hz, 2H), 3.67 (s, 3H), 2.81 (t, J=6.9 Hz, 2H).
1-(4-fluorophenyl)-3-(4-(3-(2-hydroxyethyl)phenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)urea (15).
To a solution of 2-[3-[5-amino-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]phenyl]ethanol (80 mg, 0.3 mmol) in 1,4-Dioxane (4 mL) at room temperature, 1-fluoro-4-isocyanato-benzene (107 mg, 0.8 mmol) was added and the reaction was heated at 90 o C overnight. The reaction mixture was concentrated to dryness under reduced pressure and the product was purified by preparative HPLC and then by mass directed autopreparative HPLC. Fractions containing product were pooled together and solvent was removed to obtain 15 as a white solid (10 mg, 9% yield). ¹H NMR (500 MHz, MeOD)  7.36 -7.31 (m, 3H), 7.25 -7.18 (m, 3H), 7. 5-(3-(4-fluorophenyl)ureido)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4 yl)benzyl)methanesulfonamide (16) To a solution of the corresponding amine (N-[[3-[5-amino-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]phenyl]methyl]methanesulfonamide (105 mg, 0.3 mmol) in THF (10 mL) at room temperature, 1-fluoro-4-isocyanato-benzene (124 mg,0.9 mmol) was added. The reaction was stirred overnight at room temperature. Further three equivalents of 1-fluoro-4-isocyanato-benzene were added and the reaction was stirred overnight. The reaction was concentrated to dryness and the product was purified by preparative HPLC to obtain 16 as a white solid. ¹H NMR (500 MHz, DMSO-d6)  9. 
N-(3-(
1-(4-fluorophenyl)-3-(4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)urea (18).
A stirred solution of methylhydrazine (59 mg, 1.2 mmol) and 2-(4-fluorophenyl)-3-hydroxy-prop-2-enenitrile (210 mg, 1.2 mmol) in ethanol (4 mL) was heated under reflux for 16h. After cooling to room temperature the reaction mixture was concentrated under vacuum and the crude material, which was a mixture of the two regioisomers, purified by flash column chromatography using a RediSep silica cartridge eluting with a mixture of CH 2 Cl 2 /MeOH 96/4. The separation was difficult and only a very small amount of pure desired isomer 4-(4-fluorophenyl)-1-methylpyrazol-3-amine (20 mg, 0.1 mmol, 8 % yield) was isolated. The remaining fractions were evaporated to give a mixture of regioisomers (122 mg) which was reacted in the next step.1-fluoro-4-isocyanato-benzene (86 mg,0.6 mmol) was added to a stirred solution of a mixture of 4-(4-fluorophenyl)-2-methyl-pyrazol-3-amine and 4-(4-fluorophenyl)-1-methyl-pyrazol-3-amine (120 mg, 0.6 mmol) in dry THF and the reaction stirred at room temperature overnight. After solvent removal under vacuum, the crude was washed several times with CH 2 Cl 2 giving a small fraction of pure 1-(4-fluorophenyl)-3-(4-(4-fluorophenyl)- 2-(4-Fluorophenyl)-3-oxobutanenitrile. To a solution of compound 2-(4-fluorophenyl)acetonitrile (28 g, 207 mmol, 1 eq) in EtOAc (91 g, 1.0 mol, 5 eq) was added NaH (9.95 g, 60% in mineral oil, 249 mmol, 1.2 eq) at 0°C. The mixture was stirred at 0 °C for 3 hours. The reaction was quenched with H 2 O (100 mL) at 15°C and then adjusted to pH=5-6. The mixture was filtered and filter cake was dried to give 2-(4-fluorophenyl)-3-oxobutanenitrile as an off-white solid, which was used in next step without further purification. ¹H NMR (400 MHz, CDCl 3 ) δ 7. 41-7.39 (m, 2H), 7.18-7.14 (m, 2H) 
4-(4-Fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine.
To a mixture of compound 2-(4-fluorophenyl)-3-oxobutanenitrile (62 g, 350 mmol, 1 eq) in EtOH (170 mL) was added MeNHNH 2 (40 g, 350 mmol, 1 eq) in one portion at 10-25 °C to get a red solution. The mixture was stirred at 10-25 °C for 16 hours. TLC (PE:EtOAc=1:1) showed that reactant 1 (Rf=0.7) was consumed and a new spot was formed (Rf=0.2). The mixture was concentrated and diluted with water (200 mL). The aqueous layer was extracted with EtOAc. The combined organic layers were dried and concentrated to get 4-(4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine (52 g, 253 mmol, 72 % yield) as an off-white solid, which was used in next step without further purification. ¹H NMR (400 MHz, CDCl 3 ) δ 7.28-7.25 (m, 2H), 7.14-7.10 (m, 2H), 3.69 (s, 3H) 
tert-Butyl-N-[5-(bromomethyl)-4-(4-fluorophenyl)-2-methyl-pyrazol-3-yl]-N-tert-butoxycarbonylcarbamate.
The mixture of compound tert-butyl-N-tert-butoxycarbonyl-N-[4-(4-fluorophenyl)-2,5-dimethylpyrazol-3-yl] carbamate (16.50 g, 41 mmol, 1 eq), NBS (7.24 g, 41 mmol, 1 eq) and AIBN (1.34 g, 8 mmol, 0.2 eq) in CCl 4 (160 mL) was stirred under N 2 for 16 hours at 80 °C. TLC (PE:EtOAc=3:1) showed that reactant (Rf=0.3) was consumed and the desired spot (Rf=0.5) was formed. The mixture was filtered and the mother liquid was concentrated to give tert-butyl-N-[5-(bromomethyl)-4-(4-fluorophenyl)-2-methyl-pyrazol-3-yl]-N-tert-butoxycarbonyl-carbamate (12.50 g, 26 mmol, 63% yield) was obtained as a yellow oil. ¹H NMR (400 MHz, CDCl 3 ) δ 7.38-7.36 (m, 2H), 7.16-7.14 (m, 2H), 4.48 (s, 2H), 3.74 (s, 3H), 1.36 (s, 18H). (3-(cyanomethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl) carbamate.
tert-Butyl
The mixture of tert-butyl N-[5-(bromomethyl)-4-(4-fluorophenyl)-2-methyl-pyrazol-3-yl]-N-tert-
butoxycarbonyl-carbamate (30.00 g, 62 mmol, 1 eq) and NaCN (3.04 g, 62 mmol, 1 eq) in DMF (300 mL) was stirred at 10-15°C for 2 hours. TLC (PE:EtOAc=3:1, Rf=0.60) showed the reaction was completed and a new spot was formed (Rf = 0.2). The mixture diluted with water (20 mL) and extracted with EA (3 x 50 mL). The aqueous layer was quenched with aq.NaClO (250 mL). The organic layer was washed with brine (2 x 100 mL) and concentrated. The residue was purified by silica gel column to get tert-butyl (3-(cyanomethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate (12.00 g, 24 mmol, 38% yield, 85% purity) as a yellow 
1-(3-(Cyanomethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-(4-fluorophenyl)urea (23).
To a solution of 2-(5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)acetonitrile (200.00 mg, 0.869 mmol, 1.00 eq) in THF (5.00 mL) was added 1-fluoro-4-isocyanatobenzene (119.10 mg, 0.869 mmol, 1.00 eq). The mixture was stirred at 25 °C for 16 hours. LCMS showed the reaction was completed. The reaction mixture was concentrated and the residue was purified by Prep-HPLC (basic condition) to get 23 (87.00 mg, 0/237 umol, 4 steps 30% yield, 100% purity) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.26 (s, 1H), 7.42-7.37 (m, 4H), 7.30-7.27 (m, 2 H), 7.13-7.10 (m, 2H) Butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl) acetic acid. The reaction mixture of tert-butyl (3-(cyanomethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate (2.50 g, 6 mmol, 1 eq) and NaOH (929 mg, 23 mmol, 4 eq) in EtOH (25 mL) and H 2 O (10 mL) was stirred at 70 °C for 8 hours. TLC (DCM:MeOH=10:1) showed the reaction was completed and two new desired spots were formed (Rf=0.1,Rf=0.35). The mixture was concentrated and diluted with water (20 mL). The aqueous layer was acidified with citric acid to pH=5 and extracted with EtOAc (3 x 30 mL). The combined organic layer was concentrated to get 2- 
2-(5-((tert-
tert-Butyl (4-(4-fluorophenyl)-3-(2-hydroxyethyl)-1-methyl-1H-pyrazol-5-yl)carbamate.
To a solution of 2-(5-((tert-butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)acetic acid (1.90 g, 5 mmol, 1.00 eq) in THF (20 mL) was added BH 3 .THF (1 M, 21.76 mL, 4 eq) drop-wise at 0 °C to get a solution. The reaction mixture was stirred at 25 °C for 3 hours. The reaction mixture was quenched with MeOH (10 mL) and then concentrated to get crude product. The reaction mixture was concentrated to get tert-butyl (4-(4-fluorophenyl)-3-(2-hydroxyethyl)-1-methyl-1H-pyrazol-5-yl)carbamate (2 g, crude) as a light yellow oil, which was used in next step without purification.
2-(5-Amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-ol.
To the solution of tert-butyl-(4-(4-fluorophenyl)-3-(2-hydroxyethyl)-1-methyl-1H-pyrazol-5-yl)carbamate (1.2 g, 3.6 mmol, 1 eq) in DCM (20 mL) was added EtOAc/HCl (5 g, 137 mmol, 39 eq) drop-wise at 10-25 °C to get a light yellow solution. The mixture was stirred at 10-25 °C for 16 hours. LCMS shows that reactant was consumed and the desired MS was detected. The reaction mixture was concentrated. The residue was dissolved in H 2 O (10 mL) and DCM (20 mL). HCl (2N) was added to adjust pH=3. The aqueous layer was separated and adjusted to pH=8 with saturated aqueous NaHCO 3 solution. The aqueous layer was extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine (2 x 20ml) and concentrated to get 2-(5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-ol (600 mg, 71% yield, 74% purity) as a light yellow oil. ¹H NMR (400 MHz, CDCl 3 ) δ 7.26-7.22 (m, 2H), 7.14-7.10 (m, 2H) 3 mmol, 1 eq) and 1-fluoro-4-isocyanatobenzene (41 mg, 0.3 mmol, 1 eq) in THF (1 mL) was stirred at 10-25 °C for 16 hours. LCMS showed that reactant was consumed and the desired MS was detected. The reaction mixture was concentrated to get compound 2-(4-(4-fluorophenyl)-5-(3-(4-fluorophenyl)ureido)-1-methyl-1H-pyrazol-3-yl)ethyl (4-fluorophenyl)carbamate (120 mg, crude) as a light yellow oil, which was used in next step directly.
1-(4-Fluorophenyl)-3-(4-(4-fluorophenyl)-3-(2-hydroxyethyl)-1-methyl-1H-pyrazol-5-yl)urea (19).
To the solution of 2-(4-(4-fluorophenyl)-5-(3-(4-fluorophenyl)ureido)-1-methyl-1H-pyrazol-3-yl)ethyl (4-fluorophenyl)carbamate (120 mg, 0.2 mmol, 1 eq) in EtOH (2 mL) was added the solution of NaOH/H 2 O (5 M, 235 L, 5 eq) drop-wise at 10-15 °C to get a colorless solution. The reaction mixture was stirred at 70 °C for 3 hours. LCMS showed that reactant was consumed and the desired MS was detected. The reaction mixture was concentrated and the residue was purified with prep-HPLC to obtain 19 (6 mg, 0.02 mmol, 7% yield, 97% purity) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 9.033 (s, 
1-(3-(2-(Dimethylamino)ethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-(4-fluorophenyl)urea (25).
To a solution of 2-(4-(4-fluorophenyl)-5-(2-(4-fluorophenyl)acetamido)-1-methyl-1H-pyrazol-3-yl)ethyl methanesulfonate (200 mg, 0.4 mmol, 1 eq) in DCM (2 mL) were added Me 2 NH.HCl (72 mg, 0.9 mmol, 2 eq) and TEA (112 mg, 1.1 mmol, 2.5 eq) at 0 °C to get a light yellow solution. The reaction mixture was stirred at 10-30 °C for 16 hours. LCMS showed that most of reactant was consumed and a major peak was observed. The reaction mixture was concentrated and the residue was purified with prep-HPLC to obtain 25 (19 mg, 0.05 mmol, 11% yield, 99% purity) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 9.45 (s,1H), 8.70 (s, 1H) 8.23 (s, 1H), 7.45-7.43 (m, 2H), 7.36-7.34 (m, 2H), 7.23 (m, 2H), 7.08 (m, 2H) .4 mmol, 1 eq) in DCM (3.mL) was added morpholine (116 mg, 1.3 mmol, 3 eq) at 0°C to get a colorless solution. The reaction mixture was stirred at 30 °C for 16 hours. LCMS showed that most of reactant was consumed and a major peak was observed. The reaction mixture was concentrated and the residue was purified with prep-HPLC to get 26 (35 mg, 77 mol, 17% yield, 97% purity) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 9.28 (s,1H), 8.50 (s,1H), 8.20 (s, 1H), 7.43-7.41 (m, 2H), 7.35-7.33 (m, 2H), 7.23 (m, 2H), 7.08 (m, 2H) -[5-(bromomethyl)-4-(4-fluorophenyl)-2-methyl-pyrazol-3-yl] -N-tert-butoxycarbonylcarbamate (5 g, 10 mmol, 1 eq) in DMF (60 mL) were added AcOK (3 g, 31 mmol, 3 eq) and KI (171 mg, 1 mmol, 0.1 eq). The mixture was stirred at 80 °C for 15 hours. TLC (PE:EtOAc=3:1, Rf=0.3,0.1) and LCMS showed that single-Boc, Bi-Boc and free amine were observed on LCMS. The reaction mixture was partitioned between H 2 O (200 mL) and EtOAc (100 mL). The organic phase was washed with brine (50 mL), dried over Na 2 SO 4 and concentrated. The residue was purified by column chromatography (SiO 2 , PE:EtOAc=20:1~10:1) to afford a mixture of (5- To the solution of a mixture of (5-((tert-butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)methyl acetate and the corresponding di Boc protected compound (2.2 g, 5 mmol, 1 eq) in MeOH (30 mL) was added K 2 CO 3 (1.3 g, 10 mmol, 2 eq). The mixture was stirred at 80 °C for 2 hours. LCMS showed the reaction was completed. The reaction mixture was concentrated and diluted with H 2 O (30 mL). The aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over Na 2 SO 4 and concentrated to give a mixture of tert-butyl (4-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)carbamate with the corresponding di-Boc protected and free amine, 1.5 g, crude) as a yellow oil. To the solution of a mixture of 5-((tert-butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxylic acid with the corresponding di-Boc protected and free amine (701 mg, 2.2 mmol, 1 eq) and NH 4 Cl (473 mg, 9 mmol, 4 eq) in DCM (15 mL) and DMF (3 mL) were added EDCI (551 mg, 3 mmol, 1.3 eq), HOBt (388 mg, 3 mmol, 1.3 eq), DIPEA (1.7 g, 13 mmol, 6 eq). The mixture was stirred at 25 °C for 16 hours. TLC (DCM:MeOH = 10:1, Rf = 0.4) showed the reaction was completed. The mixture was washed with water (10 mL), brine (10 mL), dried over Na 2 SO 4 and concentrated to afford a mixture of tert-butyl (3-carbamoyl-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate with the corresponding di-Boc protected and free amine (mixture, 520 mg, crude) as yellow oil which was used in next step without further purification.
5-((tert-
5-Amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide.
The reaction mixture of a mixture of tert-butyl (3-carbamoyl-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate with the corresponding di-Boc protected and free amine (520 mg, 1.6 mmol, 1 eq) in EtOAc/HCl (4 mol/L, 10 mL) was stirred at 15 °C for 15 hours. TLC (PE:EtOAc=0:1, Rf=0.15) and LCMS showed the reaction was completed. The reaction mixture was concentrated and adjusted to pH=8 with aqueous NaHCO 3 solution. The aqueous layers were extracted with EtOAc (2 x 25 mL). The combined organic layers were dried over Na To a solution of a mixture of tert-butyl (3-carbamoyl-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate with the corresponding di-Boc protected and free amine (330 mg, 1 mmol, 1 eq) and pyridine (234 mg, 3 mmol, 3 eq) in DCM (5 mL) was added TFAA (415 mg, 2 mmol, 2 eq) drop-wise at 0 °C. The mixture was stirred at 0 °C for 1 hour. TLC (PE:EtOAc = 1:1, Rf = 0.7) showed the reaction was completed. The mixture was quenched with saturated aqueous NaHCO 3 solution (5 mL) and extracted with DCM (10 mL). The organic layer was washed with brine (5 mL), dried over anhydrous Na 2 SO 4 and concentrated. The residue was purified by Prep-TLC (PE:EtOAc=1:1) to afford tert-butyl (3-cyano-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate (90 mg, 0.3 mmol, 28% yield, 95% purity) as a yellow oil. LC-MS (ESI) m/z 317 [M + H] + .
5-Amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile. Tert-butyl (3-cyano-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate (90 mg, 0.3 mmol, 1 eq) was dissolved in HCl/EtOAc (3 mL) and the reaction mixture was stirred at 25 °C for 1 hour. TLC (PE:EtOAc=1:1, Rf=0.35) showed the reaction was completed. The reaction mixture was concentrated and diluted with EtOAc (5 mL). The organic layer was washed with saturated aqueous NaHCO 3 solution (5 mL), dried over anhydrous Na 2 SO 4 and concentrated to get compound 5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (45 mg, 0.2 mmol, 73% yield) as a yellow solid.
1-(3-Cyano-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-(4-fluorophenyl)urea (22).
To the solution of 5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (45 mg, 0.2 mmol, 1 eq) in THF (2.00 mL) was added 1-fluoro-4-isocyanatobenzene (34 mg, 0.25 mmol, 1.2 eq) and the reaction mixture was stirred at 25 °C for 16 hours. LCMS showed the reaction was completed. tert-Butyl (4-(4-fluorophenyl)-3-formyl-1-methyl-1H-pyrazol-5-yl)carbamate. The reaction mixture of a mixture of tert-butyl (4-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)carbamate with the corresponding di-Boc protected and free amine (1 g, 3 mmol, 1 eq) and MnO2 (2.7 g, 31 mmol, 10 eq) in DCM (10 mL) was stirred at 20 °C for 2 hours. TLC (PE:EtOAc=2:1, Rf=0.44) showed the reaction was completed and the desired MS was observed on LCMS. The mixture was filtered and the filtrate was concentrated to get tert-butyl (4-(4-fluorophenyl)-3-formyl-1-methyl-1H-pyrazol-5-yl)carbamate (700 mg, 2.2 mmol, 70% yield) as a yellow solid. LC-MS (ESI) m/z 320 [M + H] + .
tert-Butyl(E)-(3-(2-cyanovinyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate. The reaction mixture of tert-butyl (4-(4-fluorophenyl)-3-formyl-1-methyl-1H-pyrazol-5-yl)carbamate (650 mg, 2 mmol, 1 eq), t-BuOK (275 mg, 2.4 mmol, 1.2 eq) and diethyl (cyanomethyl)phosphonate (435 mg, 2.4 mmol, 1.2 eq) in THF (7.00 mL) was stirred at 20 °C for 2 hours. Desired MS was observed on LCMS. The mixture was concentrated and diluted with water (50 mL). The aqueous layer was extracted with EtOAc (3x 50 mL). The combined organic layers were concentrated and the residue was purified by column chromatography on silica gel (PE:EtOAc=5:1~2:1) to get compound tert-butyl ( 6 mmol, 1 eq) was added to HCl/EtOAc (4 mol/L, 2 mL) and the reaction mixture was stirred at 20 °C for 8 h. TLC (PE:EtOAc=2:1, Rf=0.35) showed the reaction was completed and the desired MS was observed on LCMS. The mixture was basified to pH=8 with saturated aqueous NaHCO 3 solution and extracted with EtOAc (3 x 10 mL). The combined organic layers were concentrated to get 3-(5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)propanenitrile (150 mg, crude) as a yellow oil, which was used in next step without further purification. LC-MS (ESI) m/z 245 [M + H] + .
1-(3-(2-Cyanoethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)-3-(4-fluorophenyl)urea (24).
The reaction mixture of 3-(5-amino-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)propanenitrile (150 mg, 0.6 mmol, 1 eq) and 1-fluoro-4-isocyanatobenzene (101 mg, 0.7 mmol, 1.2 eq) in THF (2 mL) was stirred at 20 °C for 8 hours. TLC (DCM:MeOH=10:1, Rf=0.51) showed the reaction was completed and the desired MS was observed on LCMS. 5-((tert-Butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl) propanoic acid. The reaction mixture of tert-butyl (3-(2-cyanoethyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate (200 mg, 0.6 mmol, 1 eq) and NaOH (93 mg, 2.3 mmol, 4 eq) in H 2 O (460 L) and EtOH (2 mL) was stirred at 70 °C for 12 hours. TLC (PE:EtOAc=1:1, Rf=0.15) showed the reaction was completed and the desired MS was observed on LCMS. The mixture was diluted with water (10 mL) and adjusted pH=6 with HCl (2N, 2 mL) . The aqueous layer was extracted with EtOAc (3 x 20 mL). The organic layers were concentrated to get 3-(5-((tert-butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)propanoic acid (180 mg, crude) as a yellow oil, which was used in next step without further purification. LC-MS (ESI) m/z 364 [M + H] + .
tert-Butyl(3-(3-amino-3-oxopropyl)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-5-yl)carbamate. The reaction mixture of 3-(5-((tert-butoxycarbonyl)amino)-4-(4-fluorophenyl)-1-methyl-1H-pyrazol-3-yl)propanoic acid (180 mg, 0.5 mmol, 1 eq), NH 4 Cl (79 mg, 1.5 mmol, 3 eq), DIPEA (224 mg, 1.7 mmol, 3.5 eq), EDCI (95 mg, 0.5 mmol, 1 eq), HOBt (67 mg, 0.5 mmol, 1 eq) and DMF (2 mL) was stirred at 20 °C for 8 hours. TLC (DCM:MeOH=10:1, Rf=0.51) showed the reaction was completed and the desired MS was observed on LCMS. The mixture was diluted with water (10 mL). The aqueous layer was extracted with EtOAc (3x 20 mL). The combined organic layers were concentrated and the residue was purified by prep-TLC (DCM:MeOH=10:1) to get tert-butyl (3- Bennett, T.N., et al. (2004) . Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob. Agents Chemother. 48,1807 Chemother. 48, -1810 Burrows, J.W., Matthew, Vaidya, A., Kortagere, S., Fan, E., Chatterjee, A.K., Nagle, A.S., and Kato, T. (2015) . Preparation of 5-(acylamino)-4-(4-fluorophenyl)-1-methylpyrazole derivatives as antimalarial agents. MMV Medicines for Malaria Venture, Switz.; Drexel University; University of Washington. Lehane, A.M., et al. (2014) . Diverse chemotypes disrupt ion homeostasis in the malaria parasite. Mol. Microbiol. 94, [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] 
